Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Andon Health Co., Ltd. (002432.SZ)
Tianjin, CN
Andon Health Co., Ltd., founded in 1995 and headquartered in Tianjin, China, is a company dedicated to the creation, production, and sales of electronic healthcare devices and intelligent hardware. Their diverse product portfolio includes essential medical monitoring instruments like blood pressure meters, nebulizer systems, blood glucose testing kits, digital thermometers, fetal heart rate monitors, electrocardiogram (ECG) devices, and pulse oximeters. The company also offers smart consumer health technology such as smartwatches and body weight scales.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.27% | +3.40% | +1.50% | +71.86% | +84.19% | +90.53% | +100.08% | +93.43% | +847.70% | +359.86% | +760.09% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%-47.3% Q1'26: -40.5% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+37.8% ★ Q1'26: +15.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-56.7% Q1'26: +218.7% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%-21.7% Q1'26: +0.2% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%-1.7% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-1.4% ★ Q1'26: -3.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×-22.58×
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
3.23B
est: 642.00M (+403.3%)
|
2.59B
est: 2.94B (-11.9%)
|
1.37B
est: 2.81B (-51.4%)
|
3.47B
3.47B – 3.47B
+23.5% YoY
|
3.54B
3.54B – 3.54B
+2.0% YoY
|
| EBITDA |
829.08M
est: 242.07M (+242.5%)
|
709.44M
est: 861.34M (-17.6%)
|
-251.64M
est: 822.13M (-130.6%)
|
1.02B
1.02B – 1.02B
+23.5% YoY
|
1.04B
1.04B – 1.04B
+2.0% YoY
|
| EBIT |
752.66M
est: 229.52M (+227.9%)
|
677.15M
est: 802.85M (-15.7%)
|
-296.54M
est: 766.31M (-138.7%)
|
946.30M
946.30M – 946.30M
+23.5% YoY
|
965.39M
965.39M – 965.39M
+2.0% YoY
|
| Net Income |
1.25B
est: 30.87M (+3,954.1%)
|
1.67B
est: 1.34B (+25.0%)
|
2.27B
est: 1.33B (+70.3%)
|
1.51B
1.51B – 1.51B
+13.7% YoY
|
1.53B
1.53B – 1.53B
+1.1% YoY
|
| SGA |
861.37M
est: 149.74M (+475.3%)
|
855.80M
est: 880.94M (-2.9%)
|
845.71M
est: 840.85M (+0.6%)
|
1.04B
1.04B – 1.04B
+23.5% YoY
|
1.06B
1.06B – 1.06B
+2.0% YoY
|
| EPS |
2.80
est: 0.07 (+3,900.0%)
|
3.81
est: 3.07 (+24.1%)
|
5.23
est: 3.06 (+70.9%)
|
3.48
3.48 – 3.48
+13.7% YoY
|
3.52
3.52 – 3.52
+1.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-27 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-25 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 2/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 2/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 2/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 2/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 2/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 2/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-28 | A | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.17% | 64.2K | 0.65% |
| 2 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.06% | 10.4K | 0.65% |
| 3 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.05% | 35.5K | 0.55% |
| 4 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.02% | 10.5K | 0.15% |
| 5 | Goldman Sachs MarketBeta Total International Equity ETF GXUS | 0.01% | 66.7K | 0.18% |
| 6 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.31M | 0.06% |
| 7 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 45.2K | 0.48% |
| 8 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 101.9K | 0.26% |
| 9 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 5.03M | 0.06% |
| 10 | Goldman Sachs MarketBeta Emerging Markets Equity ETF GSEE | 0.00% | 2.8K | 0.45% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fei Qin | Head of Accounting Department | — | — |
| Ming Cong | Deputy GM & Employee Director | — | male |
| Tong Wu | Board Secretary | — | male |
| Yi Liu | GM & Chairman | — | male |
| Yong Wang | Deputy GM & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002432.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
